Exclusion criteria
hepatic disease, pancreatic injury, gastrointestinal or rectal bleeding, inflammatory bowel disease, ulcers, dehydration, pancreatitis, hypersensitivity, Major gastrointestinal tract
HEPATIC DISEASE, INFLAMMATORY BOWEL DISEASE, ULCERS, DEHYDRATION, URINARY TRACT OBSTRUCTION, HEPATIC ENCEPHALOPATHY, PANCREATITIS, ESOPHAGEAL VARICES, TYPE 2 DIABETES, HYPERSENSITIVITY

Diagnosis of type 1 or type 2 diabetes mellitusUrinary protein excretion of less than 500 mg/g and eGFR < 30 ml/min/1.7 mActive malignancy.Any medication, surgical or medical condition that may significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: history of active inflammatory bowel disease within the last 6 months; Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last 6 months; pancreatic injury or pancreatitis within the last six months.Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3 × ULN at the screening visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt.Evidence of urinary tract obstruction.History of hypersensitivity or contraindications to empagliflozin.Subjects who, in the assessment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data.Participation in any clinical investigation within 3 months prior to initial dosing.Pregnancy or breastfeeding.Laboratory workup included serum creatinine, estimated GFR by CKD-EPI creatinine equation, serum uric acid, serum albumin, full blood count, urine analysis, urinary protein to creatinine ratio and hemoglobin A1c.